Joanna MacEwan, PhD
Director, Policy & Economics
Dr. MacEwan is an expert in stakeholder preference elicitation and advanced econometric analyses including group-based trajectory modeling and willingness to pay evaluation. At PHE, Dr. MacEwan has used large claims data to identify the determinants of hospitalization and other patient outcomes in patients with severe mental illness and heart failure. She also has extensive experience in the valuation of treatment innovations and increased survival for cancer patients. Prior to joining PHE, Dr. MacEwan worked as a regulatory economist at the US Food and Drug Administration Center for Food Safety and Applied Nutrition in College Park, Maryland, where she conducted regulatory impact analysis on provisions of the Affordable Care Act.
PhD, Agricultural and Resource Economics, University of California, Davis
MS, Agricultural and Resource Economics, University of California, Davis
BA, Economics, University of California, Davis
ASSOCIATED CASE STUDIES
- Lakdawalla D, et al. What do pharmaceuticals really cost in the long run? Am J Manag Care. 2017.
- MacEwan JP, et al. Pattern of adherence to oral atypical antipsychotics among patients diagnosed with schizophrenia. J Manag Care Spec Pharm. 2016.
- MacEwan JP, et al. The relationship between adherence and total spending among Medicare beneficiaries with type 2 diabetes. Am J Manag Care. 2017.
- MacEwan JP, et al. The value of survival gains in pancreatic cancer from novel treatment regimens. J Manag Care Spec Pharm. 2017.
- Shafrin J, et al. Physician and patient preferences for nonvalvular atrial fibrillation therapies. Value Health. 2016.